

Date: 14th August, 2018

To,
Listing Department,
BSE Limited
Floor 25, PJ Tower
Dalal Street,
Mumbai - 400 001

**Sub.: Outcome of the proceedings of the meeting of the Board of Directors
of the Company**
Script Code: 540359

Dear Sir,

This is to inform you that Board of Directors at the meeting held today, i.e., 14th August, 2018, inter alia transacted the following business:

1. Approved, considered and taken on record the Unaudited Financial Results for the quarter ended 30th June, 2018 along with Limited Review Report of the Company.
2. The company received primary sanction of loan from HDFC Bank, RCC Bank and Kotak Mahindra Bank with respect to expansion of its plant. The Board of Directors of the company authorized Mr. Alkesh R. Gosalia, Director and Mr. Umang A. Gosalia, Director of the company to review the terms and conditions for the receipt of loan sanctioned from banks and finalize and avail bank facilities.

The Board of Directors meeting was commenced at 03:00 P.M. and concluded at 05:00 P.M.

We request you to take the above information on record.

Thanking You.

For Parmax Pharma Limited

Alkesh R. Gosalia
Alkesh R. Gosalia
Din: 01130615
Director



Statement of Standalone Unaudited Results for the Quarter ended 30.06.2018					
(in Rs.)					
Sr. No.	Particulars	Quarter Ended (30.06.2018)	Preceding Quarter ended (31.03.18)	Corresponding Quarter Ended (30.06.2017)	Previous year ended (31.03.2018)
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from Operations				
	(a) Revenue from operations	33827442	31592065	26061713	119015986
	(b) Other income	42594	181290	200880	472423
	Total income from operations (net) (a+b)	33870036	31773355	26262593	119488409
2	Expenses				
	(a) Cost of materials consumed	15243666	13289710	24823650	70645775
	(b) Purchase of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2712514	-3758815	-8477631	-12830395
	(d) Employee benefits expense	4904966	2706351	5090282	21313498
	(e) Finance Costs	65114	56933	-	335776
	(f) Depreciation and amortisation expense	2552100	3103261	2487000	10929861
	(g) Other expenses	7777540	13536115	4430804	29077352
	Total expenses	33255900	28933555	28354105	119471867
3	Profit/(Loss) from operations before exceptional items and tax (1-2)	614136	2839800	-2091512	16542
4	Exceptional Items	-	-	-	-
5	Profit/ (Loss) before tax (3-4)	614136	2839800	-2091512	16542
6	Tax expense:				
	(1) Current tax	-	-	-	250000
	(2) Deferred tax	-	-	-	(238,884.00)
7	Net Profit / (Loss) for the period from continuing operations (5-6)	614136	2839800	-2091512	5426
8	Profit/(loss) from discontinuing operations	-	-	-	-
9	Tax expense of discontinuing operations	-	-	-	-
10	Profit/(loss) from Discontinuing operations (after tax) (8-9)	-	-	-	-
11	Profit (Loss) for the period (7+10)	614136	2839800	-2091512	5426
12	Other Comprehensive Income	-	-	-	-
13	Total Comprehensive Income for the period (11+12) Comprising Profit (Loss) and Other comprehensive Income for the period)	614136	2839800	-2091512	5426
14	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000
15	Earnings per share (for continuing operation) (of Rs. /- each) (not annualised):				
	(a) Basic	0.16	0.76	-0.56	0.00
	(b) Diluted	-	-	-	-

Notes:

- The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14th August, 2018
- The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter ended 30th June, 2018
- The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
- Statement of Unaudited Financial Results of the company for the quarter ended 30th June, 2018 in the prescribed format under Schedule III of Companies Act, 2013
- The figures for the previous period have been regrouped wherever necessary.
- The company has adopted Indian Accounting Standards (Ind-AS) from 1st April, 2017 and these financial results have been prepared in accordance with the Ind-AS as specified under section 133 of Companies Act, 2013.

FOR, PARMAX PHARMA LIMITED



Alkesh Gosalia

Director

Place: Hadamtala (Rajkot)

Date: 14.08.2018



Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 Fax : +91-2827-270536 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Shailesh R Mehta
B.Com. F.C.A.

M.No. 038000

Partner
Malay B Shah
B.Com. A.C.A.

M. No. 159526

Partner
Zarna M Shah
M.Com. A.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To

The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter ended 30th June 2018 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on 14th August 2018. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRS:) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:
(O) 0281-2468261
(F) 0281-3045432
(M) 09427564149
(E) bassrmco.office@gmail.com

Or

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Shailesh R Mehta
B.Com. F.C.A.

M.No. 038000

Partner
Malay B Shah
B.Com. A.C.A.

M. No. 159526

Partner
Zarna M Shah
M.Com. A.C.A. DISA
(Information Systems Audit)
M. No. 144246

practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 14.08.2018



For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants

Zarna M Shah

ZARNA M SHAH
Partner
M. No. 144246

Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:
(O) 0281-2468261
(F) 0281-3045432
(M) 09427564149
(E) bassrmco.office@gmail.com

Or